"Shortage of Common Children's Asthma Medication Causes Parental Panic"

GlaxoSmithKline's decision to stop manufacturing the widely used asthma medication Flovent has caused concern among parents and healthcare providers, as the generic version may not be covered by some insurers. Senator Elizabeth Warren accused the company of "price gouging" and avoiding new government regulations. The move has raised worries about access to essential medication for children with asthma, particularly those from lower-income families and immigrant communities. Pharmaceutical companies are facing increased scrutiny over drug pricing and access, with implications for millions of children who rely on these medications.